• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

What does the historic settlement won by Henrietta Lacks ’s family mean for others?
Last week, the family of Henrietta Lacks settled its lawsuit against the huge biotechnology company Thermo Fisher Scientific over its claim that the company had been “unjustly enriched” by its use of her cells. Lacks was a Black woman who died of cervical cancer in 1951, soon after a doctor took a sample from her tumor without her knowledge or consent and created an immortal cell line, HeLa. No financial payments or other terms of the settlement were disclosed, and no judge ruled on the fundamentals of the unusual claim. But some have nevertheless hailed it as precedent setting. And the family ’ s la...
Source: Science of Aging Knowledge Environment - August 7, 2023 Category: Geriatrics Source Type: research

Recent progress in the immunotherapy of hepatocellular carcinoma: Non-coding RNA-based immunotherapy may improve the outcome
Biomed Pharmacother. 2023 Jun 30;165:115104. doi: 10.1016/j.biopha.2023.115104. Online ahead of print.ABSTRACTHepatocellular carcinoma (HCC) is the second most lethal cancer and a leading cause of cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) significantly improved the prognosis of HCC; however, the therapeutic response remains unsatisfactory in a substantial proportion of patients or needs to be further improved in responders. Herein, other methods of immunotherapy, including vaccine-based immunotherapy, adoptive cell therapy, cytokine delivery, kynurenine pathway inhibition, and gene delivery, h...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 2, 2023 Category: Drugs & Pharmacology Authors: Fatemeh Afra Amir Ali Mahboobipour Amir Salehi Farid Moein Ala Source Type: research

CAR-T cells development in solid tumors
Bull Cancer. 2022 Dec 19:S0007-4551(22)00436-2. doi: 10.1016/j.bulcan.2022.12.001. Online ahead of print.ABSTRACTCAR-T cells have produced very promising results in the field of onco-hematology and have been rapidly approved for marketing in France for several years now. In solid tumors, current results are more disappointing. Indeed, many hurdles come in the way. Tumor vascularization, the strongly immunosuppressive microenvironment, the loss of the target antigen as well as T cell exhaustion are part of the explanation of those results. Hence many researchers are working to develop strategies to counteract these resistan...
Source: Bulletin du Cancer - December 21, 2022 Category: Cancer & Oncology Authors: Nathan El Ghazzi Antoine Italiano Jacques-Olivier Bay Aurore Doug é Source Type: research

Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news

The Macro View – Health, Economics, and Politics and the Big Picture. What I Am Watching Here And Abroad.
August 04, 2022 Edition-----The war seems to grind on sadly and Pres. Biden is having a second round with COVID as unprecedented weather happens all over the US. It all feels rather like ‘the end of days’!In the UK we see an increasing chance of a third female PM being elected as the country seems to be struggling. We do need to remember however the UK remains a significant power with nuclear weapons and home-grown nuclear submarines!In OZ we have had last week working out how to progress the First Nations ‘Voice’ as we wrap up the 1st session of Parliament for the new Government. Comments welcome on how you think ...
Source: Australian Health Information Technology - August 4, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs

Weekly Australian Health IT Links – 25 July, 2022.
Here are a few I have come across the last week or so. Note: Each link is followed by a title and a few paragraphs. For the full article click on the link above title of the article. Note also that full access to some links may require site registration or subscription payment.General Comment-----Quite a lot going on this week and we have had a pretty busy comment flow on the blog. Interesting how comment streams evolve!The telehealth debate continues and the Government is yet to notice what a ‘steaming pile of poo’the #myHR is!-----https://www.healthcareitnews.com/news/anz/australia-launches-digital-cancer-hub-childre...
Source: Australian Health Information Technology - July 25, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs

Methodology for a correlate of protection for group B Streptococcus: Report from the Bill & amp; Melinda Gates Foundation workshop held on 10 and 11 February 2021
Vaccine. 2022 Jun 29:S0264-410X(22)00587-4. doi: 10.1016/j.vaccine.2022.05.016. Online ahead of print.ABSTRACTWorldwide, childhood mortality has declined significantly, with improvements in hygiene and vaccinations against common childhood illnesses, yet newborn mortality remains high. Group B Streptococcus (GBS) disease significantly contributes to newborn mortality and is the leading cause of meningitis in infants. Many years of research have demonstrated the potential for maternal vaccination against GBS to confer protection to the infant, and at least three vaccine candidates are currently undergoing clinical trials. G...
Source: Cancer Control - July 2, 2022 Category: Cancer & Oncology Authors: Peter B Gilbert Richard Isbrucker Nick Andrews David Goldblatt Paul T Heath Alane Izu Shabir A Madhi Lawrence Moulton Stephanie J Schrag Nong Shang George Siber Ajoke Sobanjo-Ter Meulen Source Type: research

Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment
Vaccine. 2022 Jun 14:S0264-410X(22)00755-1. doi: 10.1016/j.vaccine.2022.06.008. Online ahead of print.ABSTRACTReplication-deficient adenoviral vectors have been under investigation as a platform technology for vaccine development for several years and have recently been successfully deployed as an effective COVID-19 counter measure. A replication-deficient adenoviral vector based on the simian adenovirus type Y25 and named ChAdOx1 has been evaluated in several clinical trials since 2012. The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) was formed to evaluate the safety and other key fe...
Source: Vaccine - June 17, 2022 Category: Allergy & Immunology Authors: Pedro M Folegatti Daniel Jenkin Susan Morris Sarah Gilbert Denny Kim James S Robertson Emily R Smith Emalee Martin Marc Gurwith Robert T Chen Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO, ex-V3SWG) Source Type: research

Pages: 1  2